Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China

Detalles Bibliográficos
Autores principales: Mu, Lifeng, Zhou, Benhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999165/
https://www.ncbi.nlm.nih.gov/pubmed/31902065
http://dx.doi.org/10.1007/s12325-019-01204-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999165/
https://www.ncbi.nlm.nih.gov/pubmed/31902065
http://dx.doi.org/10.1007/s12325-019-01204-0

Ejemplares similares